138 related articles for article (PubMed ID: 38493671)
1. MDSC-targeting gold nanoparticles enhance PD-1 tumor immunotherapy by inhibiting NLRP3 inflammasomes.
Zhu Y; Chen P; Hu B; Zhong S; Yan K; Wu Y; Li S; Yang Y; Xu Z; Lu Y; Ouyang Y; Bao H; Gu W; Wen L; Zhang Y
Biomaterials; 2024 Jun; 307():122533. PubMed ID: 38493671
[TBL] [Abstract][Full Text] [Related]
2. Ablation of NLRP3 inflammasome rewires MDSC function and promotes tumor regression.
Papafragkos I; Grigoriou M; Boon L; Kloetgen A; Hatzioannou A; Verginis P
Front Immunol; 2022; 13():889075. PubMed ID: 36032139
[TBL] [Abstract][Full Text] [Related]
3. Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion.
Tengesdal IW; Menon DR; Osborne DG; Neff CP; Powers NE; Gamboni F; Mauro AG; D'Alessandro A; Stefanoni D; Henen MA; Mills TS; De Graaf DM; Azam T; Vogeli B; Palmer BE; Pietras EM; DeGregori J; Tan AC; Joosten LAB; Fujita M; Dinarello CA; Marchetti C
Proc Natl Acad Sci U S A; 2021 Mar; 118(10):. PubMed ID: 33649199
[TBL] [Abstract][Full Text] [Related]
4. Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD.
Koehn BH; Saha A; McDonald-Hyman C; Loschi M; Thangavelu G; Ma L; Zaiken M; Dysthe J; Krepps W; Panthera J; Hippen K; Jameson SC; Miller JS; Cooper MA; Farady CJ; Iwawaki T; Ting JP; Serody JS; Murphy WJ; Hill GR; Murray PJ; Bronte V; Munn DH; Zeiser R; Blazar BR
Blood; 2019 Nov; 134(19):1670-1682. PubMed ID: 31533918
[TBL] [Abstract][Full Text] [Related]
5. A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.
Theivanthiran B; Evans KS; DeVito NC; Plebanek M; Sturdivant M; Wachsmuth LP; Salama AK; Kang Y; Hsu D; Balko JM; Johnson DB; Starr M; Nixon AB; Holtzhausen A; Hanks BA
J Clin Invest; 2020 May; 130(5):2570-2586. PubMed ID: 32017708
[TBL] [Abstract][Full Text] [Related]
6. Cell-Penetrating Nanoparticles Activate the Inflammasome to Enhance Antibody Production by Targeting Microtubule-Associated Protein 1-Light Chain 3 for Degradation.
Zhu M; Du L; Zhao R; Wang HY; Zhao Y; Nie G; Wang RF
ACS Nano; 2020 Mar; 14(3):3703-3717. PubMed ID: 32057231
[TBL] [Abstract][Full Text] [Related]
7. IL-27 regulates NLRP3 inflammasome activation of MDSCs in experimental Sjögren's syndrome.
Xia X; Long Q; Zha J; Jiang T; Guo J; Jiang B; Li X; Yao G
Int Immunol; 2023 Nov; 35(11):531-542. PubMed ID: 37756640
[TBL] [Abstract][Full Text] [Related]
8. The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells.
van Deventer HW; Burgents JE; Wu QP; Woodford RM; Brickey WJ; Allen IC; McElvania-Tekippe E; Serody JS; Ting JP
Cancer Res; 2010 Dec; 70(24):10161-9. PubMed ID: 21159638
[TBL] [Abstract][Full Text] [Related]
9. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
10. Candida tropicalis induces NLRP3 inflammasome activation via glycogen metabolism-dependent glycolysis and JAK-STAT1 signaling pathway in myeloid-derived suppressor cells to promote colorectal carcinogenesis.
Zhang Z; Chen Y; Yin Y; Chen Y; Chen Q; Bing Z; Zheng Y; Hou Y; Shen S; Chen Y; Wang T
Int Immunopharmacol; 2022 Dec; 113(Pt B):109430. PubMed ID: 36384075
[TBL] [Abstract][Full Text] [Related]
11. Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma.
Chen L; Huang CF; Li YC; Deng WW; Mao L; Wu L; Zhang WF; Zhang L; Sun ZJ
Cell Mol Life Sci; 2018 Jun; 75(11):2045-2058. PubMed ID: 29184980
[TBL] [Abstract][Full Text] [Related]
12. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
13. Targeting inflammasome/IL-1 pathways for cancer immunotherapy.
Guo B; Fu S; Zhang J; Liu B; Li Z
Sci Rep; 2016 Oct; 6():36107. PubMed ID: 27786298
[TBL] [Abstract][Full Text] [Related]
14. Reactive oxygen species trigger NF-κB-mediated NLRP3 inflammasome activation induced by zinc oxide nanoparticles in A549 cells.
Liang X; Zhang D; Liu W; Yan Y; Zhou F; Wu W; Yan Z
Toxicol Ind Health; 2017 Oct; 33(10):737-745. PubMed ID: 28870124
[TBL] [Abstract][Full Text] [Related]
15. Tumor NLRP3-Derived IL-1β Drives the IL-6/STAT3 Axis Resulting in Sustained MDSC-Mediated Immunosuppression.
Tengesdal IW; Dinarello A; Powers NE; Burchill MA; Joosten LAB; Marchetti C; Dinarello CA
Front Immunol; 2021; 12():661323. PubMed ID: 34531850
[TBL] [Abstract][Full Text] [Related]
16. HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1β production via suppressing the NF-κB pathway and ROS production.
Yu X; Lan P; Hou X; Han Q; Lu N; Li T; Jiao C; Zhang J; Zhang C; Tian Z
J Hepatol; 2017 Apr; 66(4):693-702. PubMed ID: 28027970
[TBL] [Abstract][Full Text] [Related]
17. Reactive oxygen species activated NLRP3 inflammasomes prime environment-induced murine dry eye.
Zheng Q; Ren Y; Reinach PS; She Y; Xiao B; Hua S; Qu J; Chen W
Exp Eye Res; 2014 Aug; 125():1-8. PubMed ID: 24836981
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.
Bruchard M; Mignot G; Derangère V; Chalmin F; Chevriaux A; Végran F; Boireau W; Simon B; Ryffel B; Connat JL; Kanellopoulos J; Martin F; Rébé C; Apetoh L; Ghiringhelli F
Nat Med; 2013 Jan; 19(1):57-64. PubMed ID: 23202296
[TBL] [Abstract][Full Text] [Related]
19. Induction of Myeloid-Derived Suppressor Cells in Cryopyrin-Associated Periodic Syndromes.
Ballbach M; Hall T; Brand A; Neri D; Singh A; Schaefer I; Herrmann E; Hansmann S; Handgretinger R; Kuemmerle-Deschner J; Hartl D; Rieber N
J Innate Immun; 2016; 8(5):493-506. PubMed ID: 27351923
[TBL] [Abstract][Full Text] [Related]
20. LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer.
Zhao T; Liu S; Hanna NH; Jalal S; Ding X; Wan J; Yan C; Du H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
